IOVANCE BIOTHERAPEUTICS, INC.IOVAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Quogue Capital LLC | 11.60% | 30.0M | ▼ -4.24pp | 2024-03-19 |
| The Vanguard Group | 8.91% | 22.8M | — | 2024-02-13 |
| Perceptive Advisors LLC | 8.80% | 26.6M | ▲ +1.90pp | 2024-11-14 |
| BlackRock, Inc. | 7.50% | 19.1M | — | 2024-01-26 |
| MHR Capital Partners Master Account LP | 6.90% | 17.6M | — | 2024-02-09 |
| STATE STREET CORPORATION | 4.40% | 13.2M | ▼ -2.02pp | 2024-10-18 |
| Point72 Asset Management, L.P. | 0.00% | 462.3M | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-05 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 62.5K | $0.00 | $0 |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 31.2K | $0.00 | $0 |
| 2026-03-05 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 39.1K | $0.00 | $0 |
| 2026-03-05 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 31.2K | $0.00 | $0 |
| 2026-03-02 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 52.1K | $0.00 | $0 |
| 2026-03-02 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 12.3K | $0.00 | $0 |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 12.7K | $0.00 | $0 |
| 2026-03-02 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 5.5K | $0.00 | $0 |
| 2026-02-24 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 120.0K | $0.00 | $0 |
| 2026-02-10 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 40.0K | $0.00 | $0 |
1–10 of 10